Intrauterine Device Insertion: a Step for High Satisfaction

Sponsor
Assiut University (Other)
Overall Status
Completed
CT.gov ID
NCT03383432
Collaborator
(none)
88
1
2
14
6.3

Study Details

Study Description

Brief Summary

The intrauterine device is a safe, reliable and long-acting reversible contraceptive method. Instrumentation of lower genital mucosa during intrauterine device application provokes pain because it is highly sensitive to touch. Fear of pain associated with intrauterine device insertion is considered a barrier to use this contraception method.

The classic insertion instructions recommend performing bimanual examination and uterine sounding prior to intrauterine device insertion in order to confirm proper determination of uterine size and position. The pain during intrauterine device insertion could be due to cervical grasping by the tenaculum, traction on the cervical canal, stretching of the internal os by the uterine sound or the intrauterine device inserter, and lastly by irritation of the endometrial lining by the intrauterine device.

Many studies investigated the use of various analgesics in different doses and routes of administration and found out that it has a significant impact on relieving of associated pain Some technical modifications have been emerged in trial to decrease pain during intrauterine device insertion. One of them is trans-abdominal ultrasound guided intrauterine device insertion which the participant with a full bladder is subjected to intrauterine device insertion under ultrasonographic guide without using tenaculum. This method effectively decreased the pain and time of intrauterine device insertion.

A recent method named "Uterine Sounding Sparing Approach" has been reported very recently in literature by Ali et al., 2017. In this method; the sonographer performs T transvaginal ultrasound to evaluate the uterine position and the endometrial length in the sagittal view of the uterus. The intrauterine device was inserted directly into the uterine cavity without using uterine sounding.

In spite of less pain reported by trans-abdominal ultrasound guided intrauterine device insertion (no vulsellum was used), this methods also have some drawbacks, firstly; the full bladder may displace the cervix upward making the intrauterine device application not quite easy and secondly; this method needs two investigators which may distress the women who wondering about this. These two drawbacks may decrease patient's and physician's satisfaction. The uterine sounding sparing approach lacks these two drawbacks which make it more satisfying.

From above evidence, there is a strong need to compare the satisfaction rate between the two mentioned approaches in trial to answer this question. Up to our knowledge; no randomized trial has been conducted or registered to compare the satisfaction rate between two above approaches.

Condition or Disease Intervention/Treatment Phase
  • Device: Intrauterine device
  • Radiation: Ultrasound
  • Procedure: uterine sounding sparing technique
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
88 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Ultrasound-guided Approach Versus Uterine Sound-sparing Approach for Intrauterine Device Insertion a Randomized Clinical Trial
Actual Study Start Date :
Jun 1, 2019
Actual Primary Completion Date :
Jun 1, 2020
Actual Study Completion Date :
Aug 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Other: Trans-abdominal ultrasound intrauterine device group.

Those will be subjected to intrauterine device insertion under trans-abdominal ultrasound guidance. In this method the participant will be asked to have a full bladder. Full bladder helps to displace the bowel out of the pelvis and acts as an acoustic window for high frequency sound waves and to straighten the angle between the uterine body and cervix in anteverted uterus, performing the function of the tenaculum. Then, then ultrasound will be done and the intrauterine device will be introduced vaginally under ultrasound vision.

Device: Intrauterine device
Copper T 380 A

Radiation: Ultrasound
Transabdominal ultrasound

Other: Uterine Sounding Sparing intrauterine device group

The sonographer performs ultrasound using transvaginal probe to evaluate the uterine position and the endometrial length in the sagittal view of the uterus. The intrauterine device was inserted directly into the uterine cavity without using uterine sounding.

Device: Intrauterine device
Copper T 380 A

Procedure: uterine sounding sparing technique
we will insert intrauterine device without using the uterine sound and we will replace this step by ultrasound before insertion

Outcome Measures

Primary Outcome Measures

  1. Level of satisfaction of patients in both groups (satisfaction score) [5 minutes after intrauterine device insertion]

    Measured by visual analogue like scale from 0 to 10

Secondary Outcome Measures

  1. Level of reported pain (visual analogue scale ) [5 minutes after intrauterine device insertion]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 49 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Women aged 18-49 years

  2. Nonpregnant

  3. Women did not receive any analgesics or misoprostol in the 24 hours prior to insertion.

Exclusion Criteria:
  1. Women with any uterine abnormalities such as congenital anomalies, endometrial lesions, fibroids

  2. Allergy to Copper.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Women Health Hospital - Assiut university Assiut Egypt 71111

Sponsors and Collaborators

  • Assiut University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Mohammed Khairy Ali, lecturer, Assiut University
ClinicalTrials.gov Identifier:
NCT03383432
Other Study ID Numbers:
  • IUD-TAUSSA
First Posted:
Dec 26, 2017
Last Update Posted:
Feb 10, 2021
Last Verified:
Feb 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Feb 10, 2021